Intravitreal triamcinolone acetonide for exudative age related macular degeneration. - sprookjes - yvandenbroek - TriplyDB

Intravitreal triamcinolone acetonide for exudative age related macular degeneration.

Intravitreal triamcinolone acetonide for exudative age related macular degeneration.

http://www.wikidata.org/entity/Q35590749

about

Surgical implantation of steroids with antiangiogenic characteristics for treating neovascular age-related macular degeneration Surgical implantation of steroids with antiangiogenic characteristics for treating neovascular age-related macular degeneration Emerging therapies for neovascular age-related macular degeneration: state of the art Clearance of autophagy-associated dying retinal pigment epithelial cells - a possible source for inflammation in age-related macular degeneration Diffuse diabetic macular oedema treated by intravitreal triamcinolone acetonide: a comparative, non-randomised study.Cataract surgery after intravitreal injection of triamcinolone acetonide.Future pharmacological treatment options for nonexudative and exudative age-related macular degeneration.Current and future pharmacological intervention for diabetic retinopathy.Modelling the natural history of geographic atrophy in patients with age-related macular degeneration.The effects of technological advances on outcomes for elderly persons with exudative age-related macular degeneration.Diffusion of technologies for the care of older adults with exudative age-related macular degeneration.Adverse events after pars plana vitrectomy among medicare beneficiaries.Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration.Factors influencing visual acuity after intravitreal triamcinolone acetonide as treatment of exudative age related macular degeneration.Photographic estimation of the duration of high dose intravitreal triamcinolone in the vitrectomised eye Immunological factors in the pathogenesis and treatment of age-related macular degeneration.HLA and eye disease: a synopsis.Ocular morbidity associated with intravitreal triamcinolone acetonide.Complications of intravitreal triamcinolone acetonide for macular edema and predictive factors for intraocular pressure elevation Intravitreal triamcinolone acetonide: a change in a paradigm.Visual acuity and intraocular pressure after high-dose intravitreal triamcinolone acetonide in selected ocular diseases.Use of intravitreal injection of triamcinolone acetonide in the treatment of age-related macular degeneration.Combined treatment of exudative age related macular degeneration with photodynamic therapy and intravitreal triamcinolone Combined intravitreal bevacizumab and photodynamic therapy with vertiporfin for management of choroidal neovascularization secondary to age-related macular degeneration.Safety of intravitreal triamcinolone acetonide: an electrophysiologic and histopathological study in rabbits.Effect of triamcinolone acetonide on proliferation of retinal endothelial cells in vitro and in vivo.Choroidal Neovascularization Induces Retinal Edema and its Treatment Addresses this Problem.Effects of triamcinolone acetonide injections with and without preservative.Effect of photodynamic therapy with posterior sub-tenon triamcinolone acetonide on predominantly classic choroidal neovascularization: one-year results.Comparison of different techniques for purification of triamcinolone acetonide suspension for intravitreal use.Branch retinal vein occlusion treated by intravitreal triamcinolone acetonide.Ocular-hypertensive response and corneal endothelial changes after intravitreal triamcinolone injections in Chinese subjects: a 6-month follow-up study.Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide. A prospective comparative nonrandomized study.Toxicity of subretinal ribozyme to the proliferating cell nuclear antigen and 5-fluorouracil in rat eyes.Use of intravitreal triamcinolone in the management of birdshot retinochoroidopathy associated with cystoid macular oedema: a case study over a three-year period.Follow-up after intravitreal triamcinolone acetonide for exudative age-related macular degeneration.Intravitreal and posterior subtenon triamcinolone acetonide in idiopathic bilateral uveitic macular oedema.Intravitreal triamcinolone injection for chronic diffuse diabetic macular oedema.Repeated intravitreal injection of triamcinolone for exudative age-related macular degeneration.

P2860

Q24201624-1B9C8F5B-FA4E-4E47-9809-806F98D32FFB Q24243503-03B6A35B-3A5B-4F07-B9D5-C95BD45B5EC2 Q28253918-BB87DE2D-0EE7-4E5A-A231-3A27315A11DF Q30821147-69F2AB14-552D-4561-AE06-90BD25442DB1 Q31148660-04862166-D0EF-4AAB-A69C-F350E0E19E28 Q33201157-167B1817-9491-4758-B250-8677DF9E1FE9 Q33212693-618E4FAA-6705-41B3-A048-EC2D1B9D1EA6 Q33216425-771B07B9-69B1-4420-B35F-A691AB3AC350 Q33227050-4BFDEA76-F362-4F8F-B68E-FC544EA8560A Q34158108-AA2CF985-63DC-4ECB-AA4E-FE265AE06EF5 Q34503375-4AD6A720-E0ED-4102-9BC5-A3C89A48E0C8 Q34796388-1D02C3F5-3381-455C-AA1F-321BFFF1AF27 Q35591813-FD30C52E-3EF2-4F7D-8EC8-18804D498B5A Q35592674-264378A5-E42D-4FD3-98D1-488D4DCB6B6F Q35769376-98E83664-6869-4625-A576-8E0280E5F8FC Q36086191-304CBEDA-AE54-4724-880B-1A5E48F79AFD Q36324893-FF3ACD0A-2EDF-4F26-9251-DEF16F9D7BCE Q36482537-96DEDFDC-5E8E-486A-B91C-27EB8A5143A8 Q36490459-D3AA4B63-4902-4352-AC77-CD03DAF13148 Q36500994-D3BDF505-DF0C-4838-858E-E689012C63BE Q36737173-2FB52B85-846D-40F2-AF2C-1A49F1220513 Q36977430-8DD584EE-E50A-42E3-997A-723A9E890299 Q41350550-980A20F6-E223-4D70-9A32-1EFAE14244A1 Q41352529-BBE55F44-C753-449A-B961-0E2A5FA2F838 Q41895584-A9D91FB8-5314-4EE0-8240-4E15410398DD Q42026811-80CD1275-A3B8-47A8-821A-A56AA281F7B7 Q42082211-3F31E68B-C834-491A-A476-048176CB5857 Q42410041-69FA10F4-5540-44F6-B44F-288D08B20726 Q42556381-97B20A75-4B04-450E-B32E-8BC47A5252DC Q43006884-5B49B2A6-6C45-4459-BF73-C0A72FD26E42 Q44857263-8AEFBC68-3BF4-4A28-A7EB-08764B473F85 Q44927521-83706A83-3C96-449B-9437-78881B325591 Q44952432-5187072F-99CE-4009-BEC8-F254D357F5E9 Q46343147-F649B117-1F33-4EF4-A1C7-384CC8389E15 Q46610289-A68D8294-C1ED-41FF-ACB0-AF981F08C278 Q46893247-AD765480-CA36-422A-A69D-53173028AEAD Q46903674-713E7A69-8817-407E-8D26-436331FB009E Q46922688-302EF137-78F9-4DB8-B73A-FC45ABCAA0EA Q53790301-32A9E3B1-FD6C-4087-BBF8-6D186881CB46

P2860

Intravitreal triamcinolone acetonide for exudative age related macular degeneration.

http://www.wikidata.org/entity/Q35590749

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

2003年论文

@zh

2003年论文

@zh-cn

name

Intravitreal triamcinolone acetonide for exudative age related macular degeneration.

@ast

Intravitreal triamcinolone acetonide for exudative age related macular degeneration.

@en

type

label

Intravitreal triamcinolone acetonide for exudative age related macular degeneration.

@ast

Intravitreal triamcinolone acetonide for exudative age related macular degeneration.

@en

prefLabel

Intravitreal triamcinolone acetonide for exudative age related macular degeneration.

@ast

Intravitreal triamcinolone acetonide for exudative age related macular degeneration.

@en

P1433

Q35590749-05A5C97B-6C35-41A6-8277-3FC42F2D98CF

P1476

Q35590749-28260756-D395-4851-88DE-AA7F889854A4

P2093

Q35590749-62309BD6-267B-410F-BE61-BC78DBD7DD58

Q35590749-6A88C7DE-7A73-4853-8F93-EF44A9E55611

Q35590749-79AD3EE9-C0A4-4AC7-87A9-B71D9A07CF57

Q35590749-95AF36E6-9FB2-497A-9B88-D989E9D96E6C

Q35590749-ADB0B752-7396-48C4-9234-65646E449676

Q35590749-C7A401BB-6A01-49FA-8692-D7B46B244467

P2860

Q35590749-0952DA17-AA3C-42B8-9F8F-73EFEA768A34

Q35590749-0E42DBA3-E646-4E73-8370-EB1CE5920260

Q35590749-0FAFB09B-EA54-400A-84BD-762C395BEFF4

Q35590749-0FE14226-432B-4A57-909C-4828631C7370

Q35590749-15027E38-4C40-4D1C-A2DC-D31000EE78F4

Q35590749-1E74B3F8-A0C7-4793-BB5E-A95A902767A8

Q35590749-2B86403A-5E58-4AC0-BD92-F1D3FEFF25FF

Q35590749-4A456C8A-BC74-464D-B6E8-7A9B4161BB6D

Q35590749-537F82B6-1A3D-486A-A378-F257ED0BC0EA

Q35590749-6591618A-268B-4164-9A2C-F6CC190C9046

P304

Q35590749-24C751C0-65A5-4C59-AC74-7D1AE127A1CB

P31

Q35590749-65DD29D1-C91F-4A40-9078-40D6A5B86010

P356

Q35590749-3C5F80A8-B57D-4D19-A043-95A995289349

P407

Q35590749-7E117472-A254-4E4F-A865-24702F5D8F56

P433

Q35590749-1A62145C-D62A-42CC-B5E6-C26F8E0F2E8C

P478

Q35590749-756322A5-204A-4E84-91DD-FAA4BF3FE254

P577

Q35590749-1291E7AE-5A8B-4892-9115-82C0312D4D1C

P5875

Q35590749-D649EFA8-3E14-447E-AD06-784B56597457

P698

Q35590749-3C30D755-1A56-400B-AA82-67F657094795

P932

Q35590749-68984F52-04BC-467C-9856-141B37BFA3D8

P356

P1433

British Journal of Ophthalmology

P1476

Intravitreal triamcinolone acetonide for exudative age related macular degeneration.

@en

P2093

G Sauder

http://www.w3.org/2001/XMLSchema#string

I Kreissig

http://www.w3.org/2001/XMLSchema#string

J B Jonas

http://www.w3.org/2001/XMLSchema#string

P Hugger

http://www.w3.org/2001/XMLSchema#string

R Degenring

http://www.w3.org/2001/XMLSchema#string

S Panda-Jonas

http://www.w3.org/2001/XMLSchema#string

P2860

Triamcinolone acetonide modulates permeability and intercellular adhesion molecule-1 (ICAM-1) expression of the ECV304 cell line: implications for macular degeneration

Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model.

Intravitreal triamcinolone in subfoveal recurrence of choroidal neovascularisation after laser treatment in macular degeneration.

Intravitreal injection of triamcinolone for diffuse diabetic macular edema.

Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema.

Exudative macular degeneration and intravitreal triamcinolone. A pilot study.

Intravitreal triamcinolone for refractory diabetic macular edema.

The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity.

Retinal toxicity of triamcinolone acetonide in silicone-filled eyes.

Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.

P304

462-468

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/BJO.87.4.462

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

87

http://www.w3.org/2001/XMLSchema#string

P577

2003-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

277485714

http://www.w3.org/2001/XMLSchema#string

P698

12642311

http://www.w3.org/2001/XMLSchema#string

P932

1771586

http://www.w3.org/2001/XMLSchema#string